- About this Journal ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 682168, 18 pages
CD200:CD200R-Mediated Regulation of Immunity
Departments of Surgery and Immunology, University Health Network and The Toronto Hospital, Toronto, ON, Canada M5G 1L7
Received 22 October 2012; Accepted 14 November 2012
Academic Editors: R. Orentas and P. Puccetti
Copyright © 2012 Reginald M. Gorczynski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citations to this Article [3 citations]
The following is the list of published articles that have cited the current article.
- Arzu Didem Yalcin, Aykut Cilli, Atil Bisgin, Ludwig G Strauss, and Felix Herth, “Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels,” Expert Opinion on Biological Therapy, pp. 1–7, 2013.
- Saadet Gumuslu, Secil Ucar, and Ludwig G. Strauss, “Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up,” Immunopharmacology And Immunotoxicology, vol. 35, no. 4, pp. 524–527, 2013.
- Erkan Alpsoy, “There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders,” Medical Science Monitor, vol. 19, pp. 888–891, 2013.